Acute myeloid leukemia
Conditions
Interventions
Study Group:Decitabine+IA
Sponsors
Department of Hematology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Eligibility
Sex/Gender
All
Age
60 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. ALL candidates for this trial should first be participants in the "Study of optimizing induction chemotherapy for elderly patients with acute myeloid leukemia based on peripheral blasts clearance rate" trial; 2. Patients who resulted in Non-remission after the first induction can be included in this trial; 3. All patients will be evaluated by the researchers to see if they are qualified for this trial.
Exclusion criteria
Exclusion criteria: 1. Patients with ejection fraction <50% (by echocardiography or multigated acquisition scan), Heart failure (NYHA III/IV); 2. Chronic pulmonary disease causing severe anoxia; 3. Liver and renal insufficiency not caused by AML (AST, ALT, serum bilirubin, creatinine higher than 2* upper normal serum level); 4. Patients with brain function damage or other mental disease; 5. Patients undergo major operation within three weeks; 6. Patient meets the conditions of "not suitable" and "unfit for chemotherapy" in the Pre-treatment risk assessment stratification scale for elderly AML (non-M3).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete Remission Rate;Partial Remission Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival;Progression Free Survival;Relapse Free Survival; | — |
Countries
China
Contacts
Public ContactJunmin Li
Department of Hematology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Outcome results
None listed